Pharmacokinetics of antiviral agents for the treatment of cytomegalovirus infection

American Journal of Health-System Pharmacy

Volumn 62, Issue SUPPL. 1, 2005, Pages

  Baillie, G Mark ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antivirals; Compliance; Cytomegalovirus infections; Dosage; Drug administration routes; Drugs; Drugs, availability; Economics; Ganciclovir; Kidney failure; Mechanism of action; Patients; Pharmacokinetics; Resistance; Transplantation; Valganciclovir

Indexed keywords

ANTIVIRUS AGENT; BETA LACTAM ANTIBIOTIC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GANCICLOVIR; PEPTIDE TRANSPORTER 1; VALGANCICLOVIR;

CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; HUMAN; KIDNEY DISEASE; NEUTROPENIA; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOCYTOPENIA;

EID: 17444363326     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.suppl_1.s14     Document Type: Conference Paper

References (15)

1. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 2002; 35:866-72.
2. Limaye AP, Corey L, Koelle DM et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000; 356:645-9.
3. Balfour HH Jr. Antiviral drugs. N Engl J Med. 1999; 340:1255-68.
4. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev. 1999; 12:286-97.
5. McEvoy GK, ed. Ganciclovir sodium. In: AHFS Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists; 2004:784-95.
6. McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 2001; 61:1153-83.
7. Cytovene package insert. Nutley, NJ: Roche Laboratories Inc.; 2000 Sep.
8. Pescovitz MD, Pruett TL, Gonwa T et al. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Transplantation. 1998; 66:1104-7.
9. Brown F, Banken L, Saywell K et al. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet. 1999; 37:167-76.
10. Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 2000; 44:2811-5.
11. Oh DM, Han HK, Amidon GL. Drug transport and targeting. Intestinal transport. Pharm Biotechnol. 1999; 12:59-88.
12. Sugawara M, Huang W, Fei YJ et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000; 89:781-9.
13. Valcyte package insert. Nutley, NJ: Roche Laboratories Inc.; 2003 Sep.
14. Henkin CC, Griener JC, Ten Eick AP. Stability of valganciclovir in extemporaneously compounded liquid formulations. Am J Health-Syst Pharm. 2003; 60:687-90.
15. Anaizi NH, Dentinger PJ, Swenson CF. Stability of valganciclovir in an extemporaneously compounded oral liquid. Am J Health-Syst Pharm. 2002; 59:1267-70.